[1] BARTOK B, FIRESTEIN G S. Fibroblast-like synoviocytes: key effector cells inrheumatoid arthritis [J]. Immunological reviews, 2010, 233(1): 233-55.
[2] GARCIA-CARBONELL R, DIVAKARUNI A S, LODI A, et al. Critical Role of Glucose Metabolism in Rheumatoid Arthritis Fibroblast-like Synoviocytes [J]. Arthritis & rheumatology (Hoboken, NJ), 2016, 68(7): 1614-26.
[3] LU C-L, QIN L, LIU H-C, et al. Tumor Cells Switch to Mitochondrial OxidativePhosphorylation under Radiation via mTOR-Mediated Hexokinase II Inhibition - AWarburg-Reversing Effect [J]. PLOS ONE, 2015, 10(3): e0121046.
[4] RAMSAY E E, HOGG P J, DILDA P J. Mitochondrial metabolism inhibitors forcancer therapy [J]. Pharmaceutical research, 2011, 28(11): 2731-44.
[5] PEARCE E J, EVERTS B. Dendritic cell metabolism [J]. Nature reviewsImmunology, 2015, 15(1): 18-29.
[6] ZITVOGEL L, KROEMER G. Targeting dendritic cell metabolism in cancer [J]. Nature medicine, 2010, 16(8): 858-9.
[7] SMOLEN J S, ALETAHA D, MCINNES I B. Rheumatoid arthritis [J]. Lancet(London, England), 2016, 388(10055): 2023-38.
[8] ALAMANOS Y, VOULGARI P V, DROSOS A A. Incidence and prevalence ofpsoriatic arthritis: a systematic review [J]. The Journal of rheumatology, 2008, 35(7):1354-8.
[9] GREGERSEN P K, SILVER J, WINCHESTER R J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoidarthritis [J]. Arthritis and rheumatism, 1987, 30(11): 1205-13.
[10] OKADA Y, WU D, TRYNKA G, et al. Genetics of rheumatoid arthritis contributes tobiology and drug discovery [J]. Nature, 2014, 506(7488): 376-81.
[11] ROBERSON E D, BOWCOCK A M. Psoriasis genetics: breaking the barrier [J]. Trends in genetics : TIG, 2010, 26(9): 415-23.
[12] KARAMI J, ASLANI S, TAHMASEBI M N, et al. Epigenetics in rheumatoidarthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of thedisease [J]. Immunology and cell biology, 2020, 98(3): 171-86.
[13] BALANDRAUD N, PICARD C, REVIRON D, et al. HLA-DRB1 genotypes and therisk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis[J]. PloS one, 2013, 8(5): e64108.
[14] KURKó J, BESENYEI T, LAKI J, et al. Genetics of rheumatoid arthritis - acomprehensive review [J]. Clinical reviews in allergy & immunology, 2013, 45(2): 170-9.
[15] BURRAGE P S, MIX K S, BRINCKERHOFF C E. Matrix metalloproteinases: role inarthritis [J]. Frontiers in bioscience : a journal and virtual library, 2006, 11: 529-43.
[16] NELL V P, MACHOLD K P, STAMM T A, et al. Autoantibody profiling as earlydiagnostic and prognostic tool for rheumatoid arthritis [J]. Annals of the rheumaticdiseases, 2005, 64(12): 1731-6.
[17] VIATTE S, PLANT D, HAN B, et al. Association of HLA-DRB1 haplotypes withrheumatoid arthritis severity, mortality, and treatment response [J]. Jama, 2015, 313(16):1645-56.
[18] LENZ T L, DEUTSCH A J, HAN B, et al. Widespread non-additive and interactioneffects within HLA loci modulate the risk of autoimmune diseases [J]. Nature genetics, 2015, 47(9): 1085-90.
[19] HEGAB M M, ABDELWAHAB A F, RUDOLPH J M, et al. Corrigendum to "CD28and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians" [Hum. Immunol. 77 (2016) 522-526] [J]. Human immunology, 2017, 78(7-8): 521.
[20] MIAKOTKIN V A. [Genetic aspects of rheumatic diseases] [J]. Vestnik Rossiiskoiakademii meditsinskikh nauk, 1998, (12): 39-43.
[21] QIN J, XING J, LIU R, et al. Association between CD40 rs1883832 and immunerelated diseases susceptibility: A meta-analysis [J]. Oncotarget, 2017, 8(60): 102235-43.
[22] MACGREGOR A J, SNIEDER H, RIGBY A S, et al. Characterizing the quantitativegenetic contribution to rheumatoid arthritis using data from twins [J]. Arthritis andrheumatism, 2000, 43(1): 30-7.
[23] GOMEZ-CABRERO D, ALMGREN M, SJöHOLM L K, et al. High-specificitybioinformatics framework for epigenomic profiling of discordant twins reveals specificand shared markers for ACPA and ACPA-positive rheumatoid arthritis [J]. Genomemedicine, 2016, 8(1): 124.
[24] GRABIEC A M, REEDQUIST K A. The ascent of acetylation in the epigenetics ofrheumatoid arthritis [J]. Nature reviews Rheumatology, 2013, 9(5): 311-8.
[25] VIATTE S, PLANT D, RAYCHAUDHURI S. Genetics and epigenetics ofrheumatoid arthritis [J]. Nature reviews Rheumatology, 2013, 9(3): 141-53.
[26] LIU Y, ARYEE M J, PADYUKOV L, et al. Epigenome-wide association dataimplicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis [J]. Nature biotechnology, 2013, 31(2): 142-7.
[27] KLEIN K, GAY S. Epigenetics in rheumatoid arthritis [J]. Current opinion inrheumatology, 2015, 27(1): 76-82.
[28] CORLAZZOLI F, ROSSETTI S, BISTULFI G, et al. Derangement of a factorupstream of RARalpha triggers the repression of a pleiotropic epigenetic network [J]. PloS one, 2009, 4(1): e4305.
[29] MENG W, ZHU Z, JIANG X, et al. DNA methylation mediates genotype andsmoking interaction in the development of anti-citrullinated peptide antibody-positiverheumatoid arthritis [J]. Arthritis research & therapy, 2017, 19(1): 71.
[30] BUSHATI N, COHEN S M. microRNA functions [J]. Annual review of cell anddevelopmental biology, 2007, 23: 175-205.
[31] ASHTON I P, PALLETT K E, COLE D J, et al. The effect of diflufenican on lipidmetabolism in plants [J]. Biochemical Society transactions, 1991, 19(3): 320s.
[32] STANCZYK J, OSPELT C, KAROUZAKIS E, et al. Altered expression ofmicroRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblastactivation [J]. Arthritis and rheumatism, 2011, 63(2): 373-81.
[33] KAWANO S, NAKAMACHI Y. miR-124a as a key regulator of proliferation andMCP-1 secretion in synoviocytes from patients with rheumatoid arthritis [J]. Annals ofthe rheumatic diseases, 2011, 70 Suppl 1: i88-91.
[34] WANG F, ZHOU J, ZHANG Y, et al. The Value of MicroRNA-155 as a PrognosticFactor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis [J]. PloS one, 2015, 10(8): e0136889.
[35] HONDA K, LITTMAN D R. The microbiome in infectious disease and inflammation[J]. Annual review of immunology, 2012, 30: 759-95.
[36] SCHER J U, LITTMAN D R, ABRAMSON S B. Microbiome in InflammatoryArthritis and Human Rheumatic Diseases [J]. Arthritis & rheumatology (Hoboken, NJ), 2016, 68(1): 35-45.
[37] CHEN J, WRIGHT K, DAVIS J M, et al. An expansion of rare lineage intestinalmicrobes characterizes rheumatoid arthritis [J]. Genome medicine, 2016, 8(1): 43.
[38] SCHER J U, UBEDA C, ARTACHO A, et al. Decreased bacterial diversitycharacterizes the altered gut microbiota in patients with psoriatic arthritis, resemblingdysbiosis in inflammatory bowel disease [J]. Arthritis & rheumatology (Hoboken, NJ), 2015, 67(1): 128-39.
[39] MAEDA Y, TAKEDA K. Role of Gut Microbiota in Rheumatoid Arthritis [J]. Journal of clinical medicine, 2017, 6(6).
[40] HE J, WANG Y, FENG M, et al. Dietary intake and risk of rheumatoid arthritis-across section multicenter study [J]. Clinical rheumatology, 2016, 35(12): 2901-8.
[41] HU Y, SPARKS J A, MALSPEIS S, et al. Long-term dietary quality and risk ofdeveloping rheumatoid arthritis in women [J]. Annals of the rheumatic diseases, 2017, 76(8): 1357-64.
[42] KLARESKOG L, GREGERSEN P K, HUIZINGA T W. Prevention of autoimmunerheumatic disease: state of the art and future perspectives [J]. Annals of the rheumaticdiseases, 2010, 69(12): 2062-6.
[43] CHANG K, YANG S M, KIM S H, et al. Smoking and rheumatoid arthritis [J]. International journal of molecular sciences, 2014, 15(12): 22279-95.
[44] ISHIKAWA Y, TERAO C. The Impact of Cigarette Smoking on Risk of RheumatoidArthritis: A Narrative Review [J]. Cells, 2020, 9(2).
[45] ALETAHA D, SMOLEN J S. Diagnosis and Management of Rheumatoid Arthritis: AReview [J]. Jama, 2018, 320(13): 1360-72.
[46] BURMESTER G R, POPE J E. Novel treatment strategies in rheumatoid arthritis [J]. Lancet (London, England), 2017, 389(10086): 2338-48.
[47] JEON C H, AHN J K, CHAI J Y, et al. Hypoxia appears at pre-arthritic stage andshows co-localization with early synovial inflammation in collagen induced arthritis [J]. Clinical and experimental rheumatology, 2008, 26(4): 646-8.
[48] KENNEDY A, NG C T, BINIECKA M, et al. Angiogenesis and blood vessel stabilityin inflammatory arthritis [J]. Arthritis and rheumatism, 2010, 62(3): 711-21.
[49] LEE Y A, KIM J Y, HONG S J, et al. Synovial proliferation differentially affectshypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients [J]. Clinicalrheumatology, 2007, 26(12): 2023-9.
[50] PALMER C S, OSTROWSKI M, BALDERSON B, et al. Glucose metabolismregulates T cell activation, differentiation, and functions [J]. Frontiers in immunology, 2015, 6: 1.
[51] GALVáN-PEñA S, O'NEILL L A. Metabolic reprograming in macrophagepolarization [J]. Frontiers in immunology, 2014, 5: 420.
[52] BUSTAMANTE M F, GARCIA-CARBONELL R, WHISENANT K D, et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis [J]. Arthritis research & therapy, 2017, 19(1): 110.
[53] LIU C, WANG J, WAN J, et al. MOF-on-MOF hybrids: Synthesis and applications[J]. Coordination Chemistry Reviews, 2021, 432: 213743.
[54] OROOJALIAN F, KARIMZADEH S, JAVANBAKHT S, et al. Current trends instimuli-responsive nanotheranostics based on metal–organic frameworks for cancertherapy [J]. Materials Today, 2022.
[55] ORTIZ N, SKRABALAK S E. Manipulating local ligand environments for thecontrolled nucleation of metal nanoparticles and their assembly into nanodendrites [J]. Angewandte Chemie (International ed in English), 2012, 51(47): 11757-61.
[56] CARNé-SáNCHEZ A, IMAZ I, CANO-SARABIA M, et al. A spray-drying strategyfor synthesis of nanoscale metal-organic frameworks and their assembly into hollowsuperstructures [J]. Nature chemistry, 2013, 5(3): 203-11.
[57] WANG Z, HU S, YANG J, et al. Nanoscale Zr‐Based MOFs with Tailorable Size andIntroduced Mesopore for Protein Delivery [J]. Advanced Functional Materials, 2018:1707356.
[58] 冯海弟, 白云峰, 冯锋等. 纳米金属有机框架在肿瘤靶向治疗中的应用 [J]. 化学进展, 2022: 34(8)：1863.
[59] CAI W, WANG J, CHU C, et al. Metal-Organic Framework-Based Stimuli- Responsive Systems for Drug Delivery [J]. Advanced science (Weinheim, Baden- Wurttemberg, Germany), 2019, 6(1): 1801526.
[60] LI D, XU H-Q, JIAO L, et al. Metal-organic frameworks for catalysis: State of theart, challenges, and opportunities [J]. EnergyChem, 2019.
[61] XIONG F, QIN Z, CHEN H, et al. pH-responsive and hyaluronic acid-functionalizedmetal-organic frameworks for therapy of osteoarthritis [J]. Journal of nanobiotechnology, 2020, 18(1): 139.
[62] KOUSER S, HEZAM A, KHADRI M J N, et al. A review on zeolite imidazoleframeworks: synthesis, properties, and applications [J]. Journal of porous materials, 2022, (3): 29.
[63] ZHAO G, WU H, FENG R, et al. Bimetallic Zeolitic Imidazolate Framework as anIntrinsic Two-Photon Fluorescence and pH-Responsive MR Imaging Agent [J]. ACSomega, 2018, 3(8): 9790-7.
[64] YANG C, XU J, YANG D, et al. ICG@ZIF-8: One-step encapsulation of indocyaninegreen in ZIF-8 and use as a therapeutic nanoplatform [J]. Chinese Chemical Letters, 2018.
[65] ZHU H, HUANG J, CHEN H, et al. MOF-derived magnetic Co@porous carbon as adirection-controlled micromotor for drug delivery [J]. New Journal of Chemistry, 2020.
[66] LIAN Z, LU C, ZHU J, et al. Mo@ZIF-8 nanozyme preparation and its antibacterialproperty evaluation [J]. Frontiers in chemistry, 2022, 10: 1093073.
[67] WU Q, LI M, TAN L, et al. A tumor treatment strategy based on biodegradableBSA@ZIF-8 for simultaneously ablating tumors and inhibiting infection [J]. Nanoscalehorizons, 2018, 3(6): 606-15.
[68] AN L, CAO M, ZHANG X, et al. pH and Glutathione Synergistically TriggeredRelease and Self-Assembly of Au Nanospheres for Tumor Theranostics [J]. ACS appliedmaterials & interfaces, 2020, 12(7): 8050-61.
[69] RUBIO-MARTINEZ M, AVCI-CAMUR C, THORNTON A W, et al. New syntheticroutes towards MOF production at scale [J]. Chemical Society reviews, 2017, 46(11):3453-80.
[70] WANG Q, ASTRUC D. State of the Art and Prospects in Metal-Organic Framework(MOF)-Based and MOF-Derived Nanocatalysis [J]. Chemical reviews, 2020, 120(2):1438-511.
[71] ALTINTAS C, AVCI G, DAGLAR H, et al. Database for CO(2) SeparationPerformances of MOFs Based on Computational Materials Screening [J]. ACS appliedmaterials & interfaces, 2018, 10(20): 17257-68.
[72] SINGH M, BACOLLA A, CHAUDHARY S, et al. Histone Acetyltransferase MOFOrchestrates Outcomes at the Crossroad of Oncogenesis, DNA Damage Response, Proliferation, and Stem Cell Development [J]. Molecular and cellular biology, 2020, 40(18).
[73] LI X, LI X, LI D, et al. Electrochemical biosensor for ultrasensitive exosomalmiRNA analysis by cascade primer exchange reaction and MOF@Pt@MOF nanozyme [J]. Biosensors & bioelectronics, 2020, 168: 112554.
[74] RUAN X, LIU D, NIU X, et al. 2D Graphene Oxide/Fe-MOF Nanozyme Nest withSuperior Peroxidase-Like Activity and Its Application for Detection of WoodsmokeExposure Biomarker [J]. Analytical chemistry, 2019, 91(21): 13847-54.
[75] ZHONG G, LIU D, ZHANG J. The application of ZIF-67 and its derivatives:adsorption, separation, electrochemistry and catalysts [J]. Journal of Materials ChemistryA, 2018, 6.
[76] QIAN J, SUN F, QIN L. Hydrothermal synthesis of zeolitic imidazolate framework- 67 (ZIF-67) nanocrystals [J]. Materials Letters, 2012, 82: 220-3.
[77] CUTOLO M, SULLI A, PIZZORNI C, et al. Anti-inflammatory mechanisms ofmethotrexate in rheumatoid arthritis [J]. Annals of the rheumatic diseases, 2001, 60(8):729-35.
[78] KHAN Z A, TRIPATHI R, MISHRA B. Methotrexate: a detailed review on drugdelivery and clinical aspects [J]. Expert opinion on drug delivery, 2012, 9(2): 151-69.
[79] WILLIAMS A, GOODFELLOW R, TOPLEY N, et al. The suppression of ratcollagen-induced arthritis and inhibition of macrophage derived mediator release byliposomal methotrexate formulations [J]. Inflammation research : official journal of theEuropean Histamine Research Society [et al], 2000, 49(4): 155-61.
[80] WILLIAMS A S, TOPLEY N, DOJCINOV S, et al. Amelioration of rat antigeninduced arthritis by liposomally conjugated methotrexate is accompanied by downregulation of cytokine mRNA expression [J]. Rheumatology (Oxford, England), 2001, 40(4): 375-83.
[81] PRABHU P, SHETTY R, KOLAND M, et al. Investigation of nano lipid vesicles ofmethotrexate for anti-rheumatoid activity [J]. International journal of nanomedicine, 2012, 7: 177-86.
[82] HOMMA A, SATO H, TAMURA T, et al. Synthesis and optimization of hyaluronicacid-methotrexate conjugates to maximize benefit in the treatment of osteoarthritis [J]. Bioorganic & medicinal chemistry, 2010, 18(3): 1062-75.
[83] HOMMA A, SATO H, OKAMACHI A, et al. Novel hyaluronic acid-methotrexateconjugates for osteoarthritis treatment [J]. Bioorganic & medicinal chemistry, 2009, 17(13): 4647-56.
[84] SHEN S, MAMAT M, ZHANG S, et al. Synthesis of CaO(2) Nanocrystals and TheirSpherical Aggregates with Uniform Sizes for Use as a Biodegradable Bacteriostatic Agent[J]. Small (Weinheim an der Bergstrasse, Germany), 2019, 15(36): e1902118.
[85] MCINNES I B, SCHETT G. The pathogenesis of rheumatoid arthritis [J]. The NewEngland journal of medicine, 2011, 365(23): 2205-19.
[86] HETLAND M L, STENGAARD-PEDERSEN K, JUNKER P, et al. Aggressivecombination therapy with intra-articular glucocorticoid injections and conventionaldisease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinicaland radiographic results from the CIMESTRA study [J]. Annals of the rheumatic diseases,2008, 67(6): 815-22.
[87] HOES J N, JACOBS J W, BUTTGEREIT F, et al. Current view of glucocorticoid cotherapy with DMARDs in rheumatoid arthritis [J]. Nature reviews Rheumatology, 2010, 6(12): 693-702.
[88] SCOTT D L, WOLFE F, HUIZINGA T W. Rheumatoid arthritis [J]. Lancet (London, England), 2010, 376(9746): 1094-108.
[89] SMOLEN J S, LANDEWé R B M, BERGSTRA S A, et al. EULAR recommendationsfor the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2022 update [J]. Annals of the rheumatic diseases, 2023, 82(1): 3-18.
[90] DIXON W G, HYRICH K L, WATSON K D, et al. Drug-specific risk of tuberculosisin patients with rheumatoid arthritis treated with anti-TNF therapy: results from theBritish Society for Rheumatology Biologics Register (BSRBR) [J]. Annals of therheumatic diseases, 2010, 69(3): 522-8.
[91] BONGARTZ T, SUTTON A J, SWEETING M J, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J]. Jama, 2006, 295(19): 2275-85.
[92] ULBRICH W, LAMPRECHT A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases [J]. Journal of the Royal Society, Interface, 2010, 7 Suppl 1(Suppl 1): S55-66.
[93] DUAN C, YU Y, HU H. Recent progress on synthesis of ZIF-67-based materials and their application to heterogeneous catalysis [J]. Green Energy & Environment, 2022, 7(1): 3-15
修改评论